Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Almirall SA    ALM   ES0157097017

ALMIRALL SA (ALM)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bolsa De Madrid
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
8.24(c) 8.33(c) 8.3(c) 8.22(c) 8.09 Last
275 427 181 991 302 382 397 824 329 123 Volume
-1.44% +1.09% -0.36% -0.96% -1.58% Change
More quotes
Financials (€)
Sales 2017 695 M
EBIT 2017 53,4 M
Net income 2017 -42,3 M
Finance 2017 115 M
Yield 2017 1,98%
Sales 2018 738 M
EBIT 2018 107 M
Net income 2018 77,2 M
Finance 2018 186 M
Yield 2018 1,81%
P/E ratio 2017 -
P/E ratio 2018 28,13
EV / Sales2017 1,85x
EV / Sales2018 1,64x
Capitalization 1 399 M
More Financials
Company
Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production.The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research... 
Sector
Pharmaceuticals
Calendar
11/06Earnings Release
More about the company
Surperformance© ratings of Almirall SA
Trading Rating : Investor Rating :
More Ratings
Latest news on ALMIRALL SA
09/07 ALMIRALL : Phase III AMPLIFY study shows Duaklir significantly improves lung fun..
08/28 ALMIRALL : appoints Peter Guenter as new CEO
08/22 ALMIRALL : announces Ron Menezes as new President & General Manager at Aqua Phar..
07/24 ALMIRALL'S H1 RESULTS 2017 : reiterating recent Guidance
07/19ALMIRALL SA : half-yearly earnings release
07/18 ALMIRALL : collaborates with ICMAB-CSIC and Leitat Technology Center in Nanomedi..
07/10 ALMIRALL : announces Guidance Update for 2017
06/27 ALMIRALL : The European Commission (EC) approves Almirall's Skilarence® for mode..
06/22 ALMIRALL : International experts elaborate a consensus on the effects, present a..
05/30 ALMIRALL : and LEO Pharma join forces to advance dermatology research by setting..
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
Latest Tweets
09/19Almirall looks to crowdsource new skin health treatments -  
09/14Almirall renews its corporate identity, aligned with its focus on skin healt.. 
09/13Almirall launches new corporate ID to align with dermatology and aesthetic fo.. 
09/13Almirall launches new corporate ID to align with dermatology and aesthetic fo.. 
09/12“We seldom think about customers in a holistic way.” Alfonso Ugarte @almirall.. 
More tweets
Qtime:65
News from SeekingAlpha
07/11 Almirall SA (LBTSF) Updates Guidance for FY17 - Slideshow
03/21 AstraZeneca's Mistakes Mount
01/13 Almirall SA (LBTSF) Presents At 35th Annual J.P. Morgan Healthcare Conference
2016 Almirall's (LBTSF) CEO Eduardo Sanchiz on Q3 2016 Results - Earnings Call Tra..
2016 Almirall SA reports 9M results
Chart ALMIRALL SA
Duration : Period :
Almirall SA Technical Analysis Chart | ALM | ES0157097017 | 4-Traders
Technical analysis trends ALMIRALL SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 11,1 €
Spread / Average Target 37%
EPS Revisions
Managers
NameTitle
Peter Guenter Chief Executive Officer
Jorge Gallardo Ballart Chairman
Eloi Crespo Cervera Vice President-Manufacturing & Technical Services
Thomas Eichholtz Chief Scientific Officer, VP-R&D
Daniel Bravo Andreu Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL SA-44.31%1 649
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223